Dexamethasone intravitreal implant in previously treated patients with diabetic macular edema: subgroup analysis of the MEAD study

Table 2 Key efficacy endpoints in previously treated patients

Endpoint	DEX 0.7	Sham	Mean Difference	P Value
Endpoint	n = 247	n = 261	Mean Difference	P Value
Patients with BCVA ≥15-letter improvement from baseline at study end, %	21.5	11.1	10.3	0.002^b
Mean BCVA average change from baseline during the study (SD), letters^a	+3.2 (8.7)	+1.5 (7.5)	1.6	0.024^c
Mean CRT average change from baseline during the study (SD), μm^a	−126 (131)	−39 (121)	−85	<0.001^c

^aArea-under-the-curve approach
^bBased on the Cochran-Mantel-Haenszel general association test stratified by study
^cBased on an analysis of covariance model with treatment and study as factors and the baseline value as a covariate
BCVA best-corrected visual acuity, CRT central retinal thickness, DEX 0.7 dexamethasone intravitreal implant 0.7 mg; SD standard deviation

ISSN: 1471-2415